Molecular Partners AG (0QXX.L)

3,4837 -0,1363 (-3,77%) Alla chiusura: 04:47PM BST

Molecular Partners AG

Wagistrasse 14
Schlieren 8952
Switzerland
41 44 755 77 00
https://www.molecularpartners.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 167

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Patrick Amstutz Ph.D.	Co-Founder, CEO, Member of Management Board & Director	662k	N/D	1975
Dr. Michael Tobias Stumpp Ph.D.	Co-Founder, Executive VP of Projects & Member of Management Board	N/D	N/D	1972
Mr. Robert Hendriks	Senior VP of Finance	N/D	N/D	N/D
Mr. Alexander Zurcher	COO & Member of Management Board	N/D	N/D	1975
Ms. Renate Gloggner	Executive VP of People & Community and Member of Management Board	N/D	N/D	1970
Mr. Daniel Steiner Ph.D.	Senior Vice President of Research & Technology	N/D	N/D	N/D
Mr. Seth D. Lewis	Senior Vice President of Investor Relations, Communications & Strategy	N/D	N/D	N/D
Mr. Michael Pitzner	General Counsel, Compliance Officer, Senior VP Legal & Business Development	N/D	N/D	N/D
Dr. Pamela A. Trail Ph.D.	Strategic Consultant	N/D	N/D	1956
Ms. Anne Goubier D.V.M., Ph.D.	Senior Vice President of Research & Early Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Molecular Partners AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.